For research use only. Not for therapeutic Use.
A3373, a novel chemical inhibitor of Phospholipase D1 (PLD1) and PLD2, with IC50 of 325 nM and 15.15?μM, respectively, inhibits LPS-induced immune response and plays important roles in autoimmune arthritis, bone demineralization and osteoclastogenesis[1][2].
| Catalog Number | I040291 |
| CAS Number | 2324948-66-3 |
| Synonyms | N-[3,5-bis(trifluoromethyl)phenyl]-5-(hydrazinecarbonyl)-1H-indole-2-carboxamide |
| Molecular Formula | C17H9F7N2O |
| Purity | ≥95% |
| InChI | InChI=1S/C18H12F6N4O2/c19-17(20,21)10-5-11(18(22,23)24)7-12(6-10)26-16(30)14-4-9-3-8(15(29)28-25)1-2-13(9)27-14/h1-7,27H,25H2,(H,26,30)(H,28,29) |
| InChIKey | PMWWUFQRANSVCI-UHFFFAOYSA-N |
| SMILES | C1=CC2=C(C=C1C(=O)NN)C=C(N2)C(=O)NC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F |
| Reference | [1]. Won Chan Hwang, et al. Inhibition of phospholipase D1 induces immunogenic cell death and potentiates cancer immunotherapy in colorectal cancer.Exp Mol Med. 2022 Sep;54(9):1563-1576. [2]. Jin-Sil Park, et al. A newly developed PLD1 inhibitor ameliorates rheumatoid arthritis by regulating pathogenic T and B cells and inhibiting osteoclast differentiation. Immunol Lett. 2023 Sep 16:263:87-96. |
